Completed PHASE3 INTERVENTIONAL 2-arm NCT06904248

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Evaluation of the Efficacy and Safety of Meloxicam Injection for Postoperative Analgesia in Abdominal Surgery Patients: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Trial

Sponsor: Yangtze River Pharmaceutical Group Co., Ltd.

Conditions Participants With Acute Moderate to Severe Pain Following Abdominal Surgery

Interventions Meloxicam Injection Sodium Chloride Injection

Updated 1 time since 2025 Last updated: Mar 25, 2025 Started: Jan 29, 2024 Primary completion: Nov 20, 2024 Completion: Feb 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Participants With Acute Moderate to Severe Pain Following Abdominal Surgery and is currently completed. Yangtze River Pharmaceutical Group Co., Ltd. leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

1 version recorded

Completed — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yangtze River Pharmaceutical Group Co., Ltd.

Data source: Yangtze River Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cangzhou, China , Changsha, China , Changzhi, China , Chengdu, China , Guangyuan, China , Guangzhou, China , Guizhou, China , Haikou, China , Hefei, China , Hengyang, China and 6 more locations